Compare LC & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LC | PRCT |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2008 | 2021 |
| Metric | LC | PRCT |
|---|---|---|
| Price | $16.31 | $28.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $22.64 | ★ $35.44 |
| AVG Volume (30 Days) | ★ 2.5M | 1.3M |
| Earning Date | 04-27-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | 1.71 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $314,702,000.00 | $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | $14.35 | $24.52 |
| P/E Ratio | $37.68 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $9.78 | $19.35 |
| 52 Week High | $21.67 | $64.89 |
| Indicator | LC | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 67.05 |
| Support Level | $15.94 | $28.35 |
| Resistance Level | $17.41 | $29.06 |
| Average True Range (ATR) | 0.78 | 1.76 |
| MACD | -0.15 | 0.47 |
| Stochastic Oscillator | 9.17 | 98.40 |
LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.